Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The ROADMAP initiative was created to facilitate the open collaboration among a variety of stakeholders to efficiently use real world evidence (RWE) for the benefit of patients with Alzheimer’s disease and their carers. The first objective of the study is to validate a simple natural disease progression model in people with Alzheimer's disease. model validation exercise is part of our effort to identify and establish a reference sequence of events in the progression of Alzheimer's disease. The present model is part of the pre-symptomatic stage. The model will help to identify people at high risk of developing Alzheimer's disease before they show any clinical signs of the disease. It is now commonly assumed that clinical interventions will have a higher change of having a disease modifying effect if they are aimed at stages before the patients show the symptoms of cognitive decline. The model will improve our understanding of the pre-symptomatic development of the disease, help us to identify high-risk populations, improve our chances to recruit those at high risk into studies and clinical trials before they show signs of the disease, and give us the possibility to evaluate the effect of early interventions on disease trajectories.